ICT-011 / InnoCure Therapeutics - LARVOL DELTA

Preclinical characterization of ICT-011, a first-in-class, highly selective, potent and orally bioavailable MET degrader for the treatment of NSCLC harboring MET amplification [WITHDRAWN] (AACR 2025) - "These results demonstrate that ICT-011 is a first-in-class, highly selective, potent and orally bioavailable MET degrader for the treatment of NSCLC harboring MET amplification."

Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CRBN • EGFR • MET